Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON versus BYDUREON BCISE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON versus BYDUREON BCISE.
BYDUREON vs BYDUREON BCISE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
BYDUREON BCISE (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety.
2 mg subcutaneously once every 7 days (weekly).
Subcutaneous injection, 2 mg once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration for immediate-release exenatide; however, BYDUREON (extended-release) exhibits a prolonged half-life of approximately 2 weeks (mean range 14-20 days) due to encapsulation in microspheres.
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration, but the extended-release formulation provides prolonged exposure over 2 weeks via continuous release from microspheres.
Excreted primarily via renal proteolytic degradation; intact exenatide is eliminated renally. Renal clearance accounts for approximately 80% of total clearance; fecal elimination is negligible (<5%).
Excreted primarily via renal degradation; no significant biliary or fecal excretion. Approximately 70% of the dose is eliminated as intact exenatide via glomerular filtration and proteolytic catabolism.
Category C
Category C
Antidiabetic
Antidiabetic